DE60044453D1 - Gentherapie für zerebrale gefässerkrankungen - Google Patents

Gentherapie für zerebrale gefässerkrankungen

Info

Publication number
DE60044453D1
DE60044453D1 DE60044453T DE60044453T DE60044453D1 DE 60044453 D1 DE60044453 D1 DE 60044453D1 DE 60044453 T DE60044453 T DE 60044453T DE 60044453 T DE60044453 T DE 60044453T DE 60044453 D1 DE60044453 D1 DE 60044453D1
Authority
DE
Germany
Prior art keywords
cerebral
gene therapy
vascular diseases
cerebrovascular
cerebral vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60044453T
Other languages
English (en)
Inventor
Ryuichi Morishita
Toshio Ogihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anges Inc
Original Assignee
Anges MG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges MG Inc filed Critical Anges MG Inc
Application granted granted Critical
Publication of DE60044453D1 publication Critical patent/DE60044453D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE60044453T 1999-09-21 2000-09-18 Gentherapie für zerebrale gefässerkrankungen Expired - Lifetime DE60044453D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP26702499 1999-09-21
JP2000241205 2000-08-09
PCT/JP2000/006347 WO2001021214A1 (fr) 1999-09-21 2000-09-18 Thérapie génique pour troubles cérébro-vasculaires

Publications (1)

Publication Number Publication Date
DE60044453D1 true DE60044453D1 (de) 2010-07-08

Family

ID=26547690

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60044453T Expired - Lifetime DE60044453D1 (de) 1999-09-21 2000-09-18 Gentherapie für zerebrale gefässerkrankungen

Country Status (12)

Country Link
US (1) US6936594B1 (de)
EP (1) EP1132098B1 (de)
JP (1) JP4642303B2 (de)
KR (1) KR100768023B1 (de)
CN (1) CN1194762C (de)
AT (1) ATE468863T1 (de)
AU (1) AU774990B2 (de)
CA (1) CA2348906A1 (de)
DE (1) DE60044453D1 (de)
HK (1) HK1042645A1 (de)
TW (1) TWI250875B (de)
WO (1) WO2001021214A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2240999T3 (es) * 1995-08-29 2005-10-16 Anges Mg, Inc. Medicamento que contiene un gen del hgf.
CA2354029C (en) 1999-10-08 2012-01-10 Medgene Bioscience, Inc. Gene therapy for cardiomyopathy
US20020164310A1 (en) 2001-03-02 2002-11-07 Mgvs Ltd. Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
JP4441263B2 (ja) 2001-11-28 2010-03-31 アンジェスＭｇ株式会社 神経変性疾患遺伝子治療剤
JP2003238439A (ja) * 2002-02-13 2003-08-27 Yasuhiko Tabata 虚血治療剤
US20080213348A1 (en) * 2002-06-06 2008-09-04 Anges Mg, Inc. Agents for gene therapy of cerebrovascular disorders
WO2003103721A1 (ja) * 2002-06-06 2003-12-18 アンジェス エムジー株式会社 脳血管障害遺伝子治療剤
JP4716873B2 (ja) * 2003-10-14 2011-07-06 聰 竹尾 知的障害の改善剤
JP4775940B2 (ja) * 2004-06-29 2011-09-21 アンジェスＭｇ株式会社 アロディニアの治療、改善、予防剤
JPWO2006011600A1 (ja) * 2004-07-29 2008-05-01 アンジェスＭｇ株式会社 脳機能改善のための医薬および方法
EP1837034A4 (de) * 2004-11-30 2009-08-05 Anges Mg Inc Mittel zur behandlung von alzheimer-krankheit
KR20130114763A (ko) * 2005-03-31 2013-10-18 더 제너럴 하스피탈 코포레이션 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
DK2495327T3 (da) 2006-03-03 2017-01-02 Promis Neurosciences Inc Fremgangsmåder og sammensætninger til at behandle og opdage sygdomme fremkaldt af fejlfoldet SOD1
WO2016069760A1 (en) * 2014-10-31 2016-05-06 Steven Yu Method of treating dementia by intranasal administration of vegf gene therapy
EP3463575A4 (de) * 2016-06-01 2020-01-29 The University of Virginia Patent Foundation Verfahren und zusammensetzungen zur modulation lymphatischer blutgefässe im zentralen nervensystem

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686085A (en) * 1980-04-14 1987-08-11 Thomas Jefferson University Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders
JPH0741429A (ja) * 1993-07-30 1995-02-10 Mitsubishi Chem Corp 神経障害改善薬
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
JPH08231416A (ja) * 1995-02-24 1996-09-10 Mitsubishi Chem Corp 血栓症治療剤
CN1136920C (zh) * 1995-02-28 2004-02-04 加利福尼亚大学董事会 基因转移介导的血管形成疗法
ES2240999T3 (es) * 1995-08-29 2005-10-16 Anges Mg, Inc. Medicamento que contiene un gen del hgf.
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5732654A (en) * 1995-10-20 1998-03-31 The First Republic Corporation Of America Open air mariculture system and method of culturing marine animals
AU2051297A (en) 1996-02-15 1997-09-02 Chiron Corporation Gene therapy method using fgf-5
JP2001520875A (ja) 1997-10-27 2001-11-06 メルク エンド カムパニー インコーポレーテッド 血管新生の刺激のための遺伝子治療
WO1999036103A1 (en) * 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
JPH11246434A (ja) * 1998-02-25 1999-09-14 Sumitomo Pharmaceut Co Ltd ｂａｘの低下及び／又はｂｃｌ−２の増加誘導剤
US6199554B1 (en) * 1998-03-27 2001-03-13 The Brigham And Women's Hospital, Inc. Method and apparatus for combining injury-mediated therapy and drug delivery

Also Published As

Publication number Publication date
EP1132098A1 (de) 2001-09-12
EP1132098B1 (de) 2010-05-26
KR20010089469A (ko) 2001-10-06
CN1194762C (zh) 2005-03-30
TWI250875B (en) 2006-03-11
EP1132098A4 (de) 2002-07-31
US6936594B1 (en) 2005-08-30
HK1042645A1 (zh) 2002-08-23
ATE468863T1 (de) 2010-06-15
CA2348906A1 (en) 2001-03-29
CN1322143A (zh) 2001-11-14
AU7314800A (en) 2001-04-24
KR100768023B1 (ko) 2007-10-17
JP4642303B2 (ja) 2011-03-02
AU774990B2 (en) 2004-07-15
WO2001021214A1 (fr) 2001-03-29

Similar Documents

Publication Publication Date Title
ATE468863T1 (de) Gentherapie für zerebrale gefässerkrankungen
GR3036686T3 (en) Therapeutic uses of bactericidal/permeability increasing protein products
ATE466883T1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
BR9506819A (pt) Derivados de ácido micofenólico substituídos na posiçao 5
IS6170A (is) Efni til öftrunar og meðferðar mýlildis
NO931889L (no) Protease og beslektede DNA-forbindelser
ATE211129T1 (de) Inhibitoren von beta-amyloid-protein-herstellung
ATE400296T1 (de) Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
AU2378402A (en) Imaging, diagnosis and treatment of disease
DK1220852T3 (da) Substituerede diazepaner
DE60108076D1 (de) Protein c derivate
TR200200278T2 (tr) Kalsilitik bileşimler
WO2003038130A8 (en) Therapeutics and diagnostics for disorders of erythropoiesis
ES2070934T3 (es) Derivados de oxotremorina 3- o 4-sustituidos.
WO2001036462A3 (en) Protein c derivatives
AU2001230243A1 (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
ATE401337T1 (de) Antiangiogene polypeptide
DE58906618D1 (de) Strobilurinderivate, ihre Herstellung und Verwendung.
DE60035209D1 (de) Mutanten von milchsäurebakterien die mindestens eine peptidase überexprimeren
DK0657431T3 (da) 4-Phenyl-3-substituerede 1,4-dihydropyridinestere med cerebral virkning.
MXPA03010739A (es) Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas.
ITMI20001161A0 (it) Procedimento perfezionato di lavorazione delle pelli, in particolare per l'eliminazione del cromo da queste ultime, e bagno utilizzato in qu
IT1316631B1 (it) Procedimento ed impianto per il controllo del surriscaldamento diprodotti semilavorati sbozzati

Legal Events

Date Code Title Description
8364 No opposition during term of opposition